Search Results
Jul 21, 2025, 06:30 ET Denison Announces Additional High-Grade Uranium Mineralization Discovered at McClean South
the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Jul 17, 2025, 06:30 ET Orano Canada and Denison Announce SABRE 1st Production at McClean Lake
the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Jul 16, 2025, 20:00 ET Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
response, the median duration of response (DoR) was 5.6 months (95% CI: 2.8-7.0). The median follow-up was 10.6 months (95% CI: 9.7-11.5) for PFS and OS. The median PFS was 5.5 months (95% CI: 4.1-7.0). OS data was not mature with the current median OS of 10.8 months (95% CI: 6.8-NC). After data cutoff, response
More news about: Innovent Biologics
Jul 16, 2025, 06:30 ET Denison Announces Discovery of Additional High-Grade Mineralization at Gryphon and Reports Results from Successful Delineation Program
identified for possible expansion of mineral resources that are outside of the mine design outlined in the 2023 Pre-Feasibility Study ("PFS"). The delineation results demonstrate that Gryphon is an excellent high-grade basement-hosted uranium deposit that
More news about: Denison Mines Corp.
Jul 16, 2025, 05:30 ET Glenbrook Questions the Unexplained and Abrupt Departure of Tejon CFO
Brown's Departure Calls on Tejon's Independent Directors to Follow the Recommendations of Leading Proxy Advisory Firms in Adopting PFS Trusts Shareholder Proposal that Received 49.3% of the Vote PALO ALTO, Calif.,
More news about: Glenbrook Capital Management
Jul 15, 2025, 21:47 ET Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
disease control rate (DCR) of 100%. After a median follow-up of 9 months, the median progression-free survival (mPFS) was not reached, with a 9-month PFS rate of 81.4%. Regardless of KRAS/BRAF mutation status, patients can benefit from ivonescimab combination therapy. The results published at the
More news about: Akeso, Inc.
Jul 08, 2025, 08:30 ET Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
months). In the randomized, controlled BRACELET-1 study, pelareorep combined with paclitaxel yielded a 12.1-month median progression-free survival (PFS) compared to 6.4 months in the paclitaxel alone control arm. "Pelareorep represents a tipping point for immunotherapy in cold tumors," said Dr.
More news about: Oncolytics Biotech® Inc.
Jul 07, 2025, 10:01 ET Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Inc. (NYSE: MRK) announced that its phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers (
More news about: NetworkNewsWire
Jul 07, 2025, 08:30 ET Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Inc. (NYSE: MRK) announced that its phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers (
More news about: NetworkNewsWire
Jul 01, 2025, 16:05 ET ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA®
More news about: ADC Therapeutics SA
Jun 30, 2025, 08:00 ET Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
months. Secondary endpoints include time to recurrence, the median duration of response, recurrence free survival (RFS), progression free survival (PFS), safety and tolerability. "I am excited that the Phase 2 trial evaluating oral TYRA-300 in IR NMIBC is now underway," said Dr. Tom
More news about: Tyra Biosciences
Jun 30, 2025, 00:04 ET Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
effect in prolonged survival benefits: Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose
More news about: Innovent Biologics
Jun 25, 2025, 20:15 ET CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
that, compared with existing standard therapies, satri-cel offers significant advantages and clinical value in extending both progression-free survival (PFS) and overall survival (OS). The trial results have garnered widespread international attention and recognition, providing a solid evidentiary foundation
More news about: CARsgen Therapeutics
Jun 25, 2025, 07:30 ET FOUNDATION SOURCE ACQUIRES PACIFIC FOUNDATION SERVICES, SOLIDIFYING POSITION AS LEADING PROVIDER OF PHILANTHROPIC SOLUTIONS
Pacific Foundation Services (PFS), a foundation management organization based in San Francisco providing philanthropic strategy, grants management, and
More news about: Foundation Source
Jun 25, 2025, 07:00 ET Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
outcomes. Among 25 evaluable patients: 3 achieved Partial Response (PR) and 10 achieved Stable Disease (SD). Two patients had Progression-Free Survival (PFS) exceeding 21 months. Senhwa is currently in active discussions with several potential collaborators. Pidnarulex (CX-5461): Broad-Spectrum
More news about: Senhwa Biosciences, Inc.
Jun 25, 2025, 07:00 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer
FRα expression levels or prior lines of therapy) in the dose-escalation and expansion study, the therapy achieved a median progression-free survival (PFS) of 7.63 months, with an objective response rate (ORR) of 40.7% and disease control rate (DCR) of 80.5%. Importantly, no cases of interstitial lung disease
More news about: Bio-Thera Solutions, Ltd
Jun 24, 2025, 12:08 ET Ovarian Cancer Drugs Market Size expected to reach US$ 4.23 billion by 2031 | The Insight Partners
approach for improving clinical outcomes in advanced ovarian cancer. These inhibitors offer long-term efficacy and can enhance progression-free survival (PFS) in newly diagnosed patients who achieve a complete response (CR) after the first, second, or third rounds of platinum-based chemotherapy.Rising
More news about: The Insight Partners
Jun 24, 2025, 08:00 ET TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
trial is ORR with a key secondary endpoint of PFS. Other secondary endpoints are safety, duration of response, and overall survival. Accelerated approval is based on the successful achievement of the ORR primary endpoint. The key secondary endpoint of PFS, if successfully achieved without a detrimental
More news about: TuHURA Biosciences, Inc.
Jun 24, 2025, 06:30 ET Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
neladalkib monotherapy or ALECENSA® (alectinib) monotherapy. The primary endpoint is progression free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include PFS based on investigator's assessment, and BICR assessment of objective response rate (ORR), intracranial objective
More news about: Nuvalent, Inc.
Jun 23, 2025, 07:00 ET Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore
More news about: Leap Therapeutics, Inc.
Jun 20, 2025, 09:21 ET With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced
More news about: USA News Group
Jun 19, 2025, 12:30 ET RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin's Lymphoma
Hodgkin's lymphoma. Known as the Early-stage Hodgkin International Prognostication Index (E-HIPI), the model estimates two-year progression-free survival (PFS) and is designed to support more personalized treatment planning for clinicians and patients.
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Jun 16, 2025, 09:00 ET AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
follow-up of 45.5 months (range, 3.1–62.8), the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reachedKM estimates of 48-m PFS rate are 52.5% for all patients and 53.4% for LBCL patients, respectivelyKM estimates of 48-m OS rate
More news about: AbelZeta Pharma, Inc.
Jun 16, 2025, 07:15 ET ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
maintained in 17 of 18 CR patients who achieved CR, with longest duration of CR of 27 months from start of treatmentProgression-free survival (PFS) was 92.9% at 12 months27 enrolled patients experienced adverse events (AE), consistent with the known safety profile of ZYNLONTA and most commonly
More news about: ADC Therapeutics SA
Jun 16, 2025, 07:00 ET PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed. The trial is being conducted at seven sites in Australia
More news about: Amplia Therapeutics Ltd